Strong TSX-V Debut by MediPharm Labs
Strong TSX-V Debut by MediPharm Labs
Perth, Oct 5, 2018 AEST (ABN Newswire) - MMJ PhytoTech Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") is delighted to note that MediPharm Labs Inc. ("MediPharm Labs") (TSX-V: LABS) made a strong debut overnight on the TSX Venture Exchange ("TSX-V") with its shares closing at CAD$2.29, 169% above MMJ's entry cost.

MMJ has CAD$5 million of equity invested in MediPharm Labs with 5.88 million shares (CAD$0.85 cost per share) and 2.94 million warrants (exercisable at CAD$1.20 per share by October 2020). The current market value of this investment is AUD$18.2 million with an unrealised MOIC(see Note below) of 3.6x.

Note: "MOIC" is multiple on invested capital (pre-tax and transaction costs). Assumes that MMJ does not need to invest further capital to exercise the warrants to capture the gain arsing from the difference between the current closing share price and the warrant exercise price.


About MMJ PhytoTech Ltd

Phytotech Medical ASX:PYL

MMJ PhytoTech Limited (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/

      


Contact

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjphytotech.com.au



Related Companies

MMJ PhytoTech Ltd   

ABN Newswire This Page Viewed:  (Last 7 Days: 191) (Last 30 Days: 986) 
ANALYTICS: LOGIN HERE

MMJ PhytoTech Ltd NEWS: RECENT VISITS (55005)

Research Report

Social Media